Moderna, Novovax stocks slide after Trump nominates Robert F. Kennedy Jr. to be top health official

With Robert F. Kennedy Jr. taking a prominent position in health policy, companies like Moderna (MRNA) and Novavax (NVAX) may face increased scrutiny and skepticism, potentially resulting in weakened trust in their products. Investors may be concerned that this political change could lead to reduced vaccination rates and altered public health policies, negatively impacting profits for these companies.

Similar to Moderna, Novavax (NVAX) is likely to experience downward pressure as market sentiment shifts unfavorably due to the nomination of Kennedy. This could hinder investor confidence in future vaccine sales and contracts, leading to a further decline in stock value for Novavax.